Amarin Corporation (AMRN) Symphony Data Shows Vacepta in Uptrend - Cantor Fitzgerald

June 11, 2021 8:10 AM EDT
Get Alerts AMRN Hot Sheet
Price: $5.40 -0.74%

Rating Summary:
    11 Buy, 10 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $10.00 price target on Amarin Corporation (NASDAQ: AMRN) noting that Symphony Health data for of TRx and NRx for Vascepa have increased meaningfully since pre-REDUCE-IT levels. The actual number of Rxs for Vascepa is underrepresented by data sources such as Symphony, which counts 30-day and 90-day Rxs as one Rx. Therefore the analyst normalized the TRx and NRx count values by dividing the quantity of 1-gram pills by 120 to get to the number of bottles prescribed (for 0.5-gram pills, divide by 240).

For the 30 and 90 day Vacepta Rxs, the analyst noted "We have seen a positive trend since 6/30/17, and the relative percentages for normalized TRx and NRx data as of 6/4/21 showed increases of 149% and 173%, respectively. This is also in an uptrend."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $4.88 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cantor Fitzgerald, Louise Chen